Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
300 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
NCT00068081
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
NCT00300222
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
NCT00115310
Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain
NCT00034710
Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
NCT00064623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants who complete the study evaluations for 12 weeks will have the option of receiving up to 3 additional open-label re-treatments over 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capsaicin Dermal Patch
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be diagnosed with PHN and be at least 6 months after crusting of the skin vesicles, with moderate to severe pain.
* Must not have significant pain due to causes other than PHN (for example, arthritis).
* Painful areas should not be located on the face, above the hairline of the scalp, and/or in proximity to mucous membranes.
* Must have intact and unbroken skin at the treatment area.
* Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (1-year).
* Must not have any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of pain.
* Must not use topical pain medications for PHN.
* Must be able to comply with study requirements such as completing a daily pain diary, attending study visits and refraining from extensive travel during study participation.
* No significant medical problems of the heart, kidneys, liver or lungs, or cancer.
* No history or current problem with substance abuse.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NeurogesX
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NeurogesX Investigational Site
Huntsville, Alabama, United States
NeurogesX Investigational Site
Phoenix, Arizona, United States
NeurogesX Investigational Site
Scottsdale, Arizona, United States
NeurogesX Investigational Site
Tucson, Arizona, United States
NeurogesX Investigational Site
Little Rock, Arkansas, United States
NeurogesX Investigational Site
La Jolla, California, United States
NeurogesX Investigational Site
San Francisco, California, United States
NeurogesX Investigational Site
Denver, Colorado, United States
NeurogesX Investigational Site
Melbourne, Florida, United States
NeurogesX Investigational Site
Naples, Florida, United States
NeurogesX Investigational Site
Ocala, Florida, United States
NeurogesX Investigational Site
Palm Beach Garden, Florida, United States
NeurogesX Investigational Site
Plantation, Florida, United States
NeurogesX Investigational Site
Sarasota, Florida, United States
NeurogesX Investigational Site
St. Petersburg, Florida, United States
NeurogesX Investigational Site
Boston, Massachusetts, United States
NeurogesX Investigational Site
Kansas City, Missouri, United States
NeurogesX Investigational Site
Las Vegas, Nevada, United States
NeurogesX Investigational Site
Morristown, New Jersey, United States
NeurogesX Investigational Site
Albany, New York, United States
NeurogesX Investigational Site
Rochester, New York, United States
NeurogesX Investigational Site
Eugene, Oregon, United States
NeurogesX Investigational Site
Memphis, Tennessee, United States
NeurogesX Investigational Site
Austin, Texas, United States
NeurogesX Investigational Site
Dallas, Texas, United States
NeurogesX Investigational Site
San Antonio, Texas, United States
NeurogesX Investigational Site
Salt Lake City, Utah, United States
NeurogesX Investigational Site
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.